FOLD רווח נקי למניה ב-12 החודשים האחרונים amicusrx.com
The dedication of scientists to combating rare pathologies guarantees Amicus Therapeutics (FOLD) exceptional staff stability. High margins are secured by patents in the gene therapy segment, while steady demand for the key drug creates a reliable cash flow. Net income per share over the last four quarters demonstrates the operational strength of the business, where -0.09 represents the latest level value.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_FOLD_-_Amicus-Therapeutics_-_Earnings-per-share-for-the-last-four-quarters "Amicus Pharma - רווח נקי למניה (EPS TTM) FOLD (תקופה 04.07.2022 - 09.05.2026) | 👁️GURU.Markets👁️")
פילוחים אנליטיים ודוחות נתונים של חברת Amicus Therapeutics Inc (FOLD)
For investors in Amicus Therapeutics (FOLD), the balance between R&D expenditures and the commercialization of Fabry disease therapy determines the business's actual market value. The rolling net income per share aggregates the annual financial result divided by the current number of securities, allowing for an objective assessment of rare drug monetization efficiency without distortions from share issuances.
